Lido Advisors LLC Buys 18,656 Shares of Zimmer Biomet Holdings, Inc. $ZBH

Lido Advisors LLC increased its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 6.1% in the 1st quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 323,507 shares of the medical equipment provider’s stock after purchasing an additional 18,656 shares during the quarter. Lido Advisors LLC’s holdings in Zimmer Biomet were worth $29,322,000 at the end of the most recent quarter.

A number of other institutional investors have also added to or reduced their stakes in the stock. DV Equities LLC bought a new position in Zimmer Biomet in the 4th quarter worth about $25,000. Monetary Solutions Ltd purchased a new stake in shares of Zimmer Biomet in the fourth quarter worth about $30,000. Gen Wealth Partners Inc bought a new position in shares of Zimmer Biomet in the fourth quarter valued at approximately $31,000. Flagship Harbor Advisors LLC purchased a new position in Zimmer Biomet during the fourth quarter valued at approximately $32,000. Finally, Headlands Technologies LLC bought a new stake in Zimmer Biomet during the 2nd quarter worth approximately $37,000. Hedge funds and other institutional investors own 88.89% of the company’s stock.

Insider Activity at Zimmer Biomet

In related news, insider Sang Yi sold 5,000 shares of the firm’s stock in a transaction dated Friday, May 29th. The stock was sold at an average price of $82.64, for a total transaction of $413,200.00. Following the transaction, the insider directly owned 27,251 shares of the company’s stock, valued at approximately $2,252,022.64. This trade represents a 15.50% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Company insiders own 1.28% of the company’s stock.

Zimmer Biomet Price Performance

Shares of NYSE:ZBH opened at $88.79 on Thursday. The company’s fifty day moving average price is $87.61 and its 200-day moving average price is $89.80. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.73 and a quick ratio of 0.95. The firm has a market capitalization of $17.18 billion, a price-to-earnings ratio of 23.06, a PEG ratio of 2.62 and a beta of 0.46. Zimmer Biomet Holdings, Inc. has a one year low of $79.12 and a one year high of $108.29.

Zimmer Biomet (NYSE:ZBH) last announced its earnings results on Tuesday, April 28th. The medical equipment provider reported $2.09 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.86 by $0.23. Zimmer Biomet had a net margin of 9.05% and a return on equity of 13.24%. The company had revenue of $2.09 billion during the quarter, compared to analyst estimates of $2.07 billion. During the same period in the previous year, the business earned $1.81 earnings per share. The firm’s quarterly revenue was up 9.3% compared to the same quarter last year. Zimmer Biomet has set its FY 2026 guidance at 8.400-8.550 EPS. On average, equities research analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.48 earnings per share for the current fiscal year.

Zimmer Biomet Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, July 31st. Stockholders of record on Thursday, June 25th will be issued a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a dividend yield of 1.1%. The ex-dividend date is Thursday, June 25th. Zimmer Biomet’s dividend payout ratio is presently 24.94%.

Analysts Set New Price Targets

Several analysts have issued reports on ZBH shares. Wells Fargo & Company lowered their target price on shares of Zimmer Biomet from $98.00 to $90.00 and set an “equal weight” rating on the stock in a research note on Wednesday, April 29th. Truist Financial reiterated a “hold” rating and issued a $92.00 price objective (down from $98.00) on shares of Zimmer Biomet in a research report on Wednesday, April 29th. Barclays dropped their price objective on Zimmer Biomet from $100.00 to $94.00 and set an “underweight” rating for the company in a research note on Wednesday, April 29th. Citigroup decreased their target price on Zimmer Biomet from $95.00 to $93.00 and set a “neutral” rating on the stock in a research note on Thursday, May 28th. Finally, BMO Capital Markets began coverage on Zimmer Biomet in a report on Wednesday, July 8th. They issued a “market perform” rating and a $95.00 price target on the stock. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, twelve have assigned a Hold rating and four have given a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $100.70.

Zimmer Biomet Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.